IP Library Granted Patent US 9,814,769
Granted Patent B2
US 9,814,769 · App. 14/872,044 · Granted Nov 14, 2017

Vaccines against pathogenic

Inventors: Haitham Tawfiq Ghunaim (Al-Sadd, QA); Marawan A. Abu Madi (Doha, QA); Andrew Potter (Saskatoon, CA); Brenda Allan (Saskatoon, CA)
Assignee: QATAR UNIVERSITY
A61K39/0258A61K39/102C07K14/245C07K14/285A61K2039/53A61K2039/541A61K2039/552C07K2319/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,814,769
App. No.
14/872,044
Granted
Nov 14, 2017
Kind
B2
Abstract

Provided herein are compositions and methods for vaccinating against infection with pathogenic Escherichia coli ( E. coli ). In some embodiments, the compositions may include a vaccine including an immunogenic portion of at least two E. coli proteins described herein.

Claims (5)

1. A composition comprising leukotoxin A set forth as SEQ.ID.NO:19 or SEQ.ID.NO: 20 and an immunogenic portion of at least two isolated proteins selected from the group consisting of: Pap fimbrial adhesin PapG protein set forth as SEQ ID NO: 4, SEQ ID NO: 23, or SEQ ID NO: 24 or 80% sequence identity with the PapG protein of SEQ ID NO: 4, SEQ ID NO: 23, or SEQ ID NO: 24, Type 1 fimbrial adhesin FimH protein set forth as SEQ ID NO: 2 or SEQ ID NO: 25 or 80% sequence identity with the FimH protein of SEQ ID NO: 2, SEQ ID NO: 25 and ferric aerobactin receptor lutA protein set forth as SEQ ID NO: 6 or SEQ ID NO: 26, or 80% sequence identity with the lutA protein of SEQ ID NO: 6 or SEQ ID NO: 26 , wherein the immunogenic portion comprises at least 20 amino acid of SEQ ID NO: 4, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 2, SEQ ID NO: 25, SEQ ID NO: 6 or SEQ ID NO: 26 wherein the leukotoxin A is fused or conjugated to the immunogenic portion of PapG, FimH, and/or lutA.

2. The composition of claim 1 , further comprising an adjuvant.

3. The composition of claim 2 , wherein the adjuvant is selected from chitosan, an oil emulsion, a toxin, an aluminum salt, alum, a mineral oil, squalane, thimerosal, interleukin-1, interleukin-2, interleukin-12, Freund's complete adjuvant, Freund's incomplete adjuvant, a polymer, and CpG.

4. The composition of claim 1 , further comprising at least one pharmaceutically acceptable excipient.

5. A kit comprising the composition of claim 1 , and instructions for administration of the composition to a subject.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2016
From: GHUNAIM, HAITHAM TAWFIQ; ABU MADI, MARAWAN A.; POTTER, ANDREW; ALLAN, BRENDA
To: QATAR UNIVERSITY
Reel/Frame 040019/0666 →
Continuity (2)
Provisional Application 62057857 · Sep 30, 2014
Related Publication 20160106826A1 · Apr 21, 2016